	US 12,257,273 B2
	Compositions comprising bacteria for cancer immunotherapy
Miguel Ángel Barajas Vélez, Pamplona (ES); and Alfredo Resano Lizaldre, Pamplona (ES)
Assigned to TRIM BIOTECH, S.L., Pamplona (ES)
Appl. No. 18/257,170
Filed by TRIM BIOTECH, S.L., Pamplona (ES)
PCT Filed Dec. 13, 2021, PCT No. PCT/EP2021/085474 § 371(c)(1), (2) Date Jun. 13, 2023, PCT Pub. No. WO2022/128909, PCT Pub. Date Jun. 23, 2022.
Claims priority of application No. 20383089 (EP), filed on Dec. 14, 2020.
Prior Publication US 2024/0091276 A1, Mar. 21, 2024
Int. Cl. A61K 35/74 (2015.01); A61K 31/7004 (2006.01); A61K 35/13 (2015.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)

CPC A61K 35/74 (2013.01) [A61K 31/7004 (2013.01); A61K 35/13 (2013.01); A61K 39/0011 (2013.01); A61P 35/00 (2018.01)]

22 Claims

1. An immunogenic composition comprising:

a) a bacterial population comprising Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, and Moraxella catarrhalis, wherein the bacteria are whole inactivated bacteria that retain the integrity of their bacterial cell wall, and

(b) one or more tumor antigenic determinants.